KINARUS THERAPEUTICS HOLDING AG |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.43 CHF | +6.71% |
|
-48.12% | +370.42% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
More news
More press releases
More news
| 1 day | +6.71% | ||
| Current month | -47.73% | ||
| 1 month | -52.96% | ||
| 3 months | -62.37% | ||
| 6 months | +213.62% | ||
| Current year | +370.42% |
1 month
7.70
17.92
Current year
1.7933.15
1 year
0.9059.14
3 years
0.90230.27
5 years
0.90230.27
10 years
0.90230.27
Kinarus Therapeutics Holding AG is a Switzerland-based Company that operates as a biopharmaceutical industry engaged in diseases treatment. The Company conducts its work within clinical-stage area and its activities include discovery, examination and development of medicines that are intended for the treatment of viral, respiratory, and ophthalmic diseases. Kinraus therapeutic drug is patent protected KIN001 which is a combination of pamapimod and pioglitazone. KIN0001 offers oral, long-term treatment of diseases with severe impact on the comfort of living.
Sector
-
- Stock Market
- Equities
- CURE Stock